{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:18:26Z","timestamp":1773299906330,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Clopidogrel is a potent drug for prevention of adverse effects during and after coronary intervention. Increasing experience indicates that a significant proportion of patients do not respond adequately to clopidogrel. Because failure of antiplatelet therapy can have severe consequences, there is need for a reliable assay to quantify the effectiveness of clopidogrel treatment.<\/jats:p>\n               <jats:p>Methods: Of 24 healthy volunteers admitted to the study, 18 were treated for 1 week with clopidogrel (300-mg loading dose and 75-mg maintenance dose), and 6 with placebo. Platelet function was monitored by 2 assays, based on flow cytometry and enzyme immunoassay, that measure the phosphorylation status of vasodilator-stimulated phosphoprotein (VASP) and by aggregometry, flow cytometry of P-selectin, and the platelet function analyzer at baseline, on days 1\u20135, and on day 9 of treatment.<\/jats:p>\n               <jats:p>Results: Aggregometry and VASP phosphorylation revealed a loss of platelet response to ADP within 12 h after clopidogrel intake. The phosphorylation status of VASP correlated with the inhibition of platelet aggregation. In contrast, neither P-selectin expression nor PFA-100 closure time was a clear indicator of clopidogrel effects on platelets.<\/jats:p>\n               <jats:p>Conclusions: VASP phosphorylation assays are reliable for quantifying clopidogrel effects. Because the VASP assay directly measures the function of the clopidogrel target, the P2Y12 receptor, the assay is selective for clopidogrel effects rather than effects of other platelet inhibitors commonly in use.<\/jats:p>","DOI":"10.1373\/clinchem.2004.047050","type":"journal-article","created":{"date-parts":[[2005,4,8]],"date-time":"2005-04-08T00:43:58Z","timestamp":1112921038000},"page":"957-965","source":"Crossref","is-referenced-by-count":138,"title":["Monitoring of Clopidogrel Action: Comparison of Methods"],"prefix":"10.1093","volume":"51","author":[{"given":"Jo\u0308rg","family":"Geiger","sequence":"first","affiliation":[{"name":"Institut fu\u0308r Klinische Biochemie und Pathobiochemie und Zentrallabor and Rudolf-Virchow Zentrum fu\u0308r Experimentelle Biomedizin,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lino","family":"Teichmann","sequence":"first","affiliation":[{"name":"Institut fu\u0308r Klinische Biochemie und Pathobiochemie und Zentrallabor and Rudolf-Virchow Zentrum fu\u0308r Experimentelle Biomedizin,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Grossmann","sequence":"first","affiliation":[{"name":"Institut fu\u0308r Klinische Biochemie und Pathobiochemie und Zentrallabor and Rudolf-Virchow Zentrum fu\u0308r Experimentelle Biomedizin,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barsom","family":"Aktas","sequence":"first","affiliation":[{"name":"Universita\u0308t Wu\u0308rzburg, Wu\u0308rzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Steigerwald","sequence":"first","affiliation":[{"name":"Institut fu\u0308r Klinische Biochemie und Pathobiochemie und Zentrallabor and Rudolf-Virchow Zentrum fu\u0308r Experimentelle Biomedizin,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Walter","sequence":"first","affiliation":[{"name":"Institut fu\u0308r Klinische Biochemie und Pathobiochemie und Zentrallabor and Rudolf-Virchow Zentrum fu\u0308r Experimentelle Biomedizin,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Schinzel","sequence":"first","affiliation":[{"name":"vasopharm BIOTECH GmbH, Wu\u0308rzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"2020022800545610900_R1","doi-asserted-by":"crossref","unstructured":"Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358:527-533.","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"2020022800545610900_R2","doi-asserted-by":"crossref","unstructured":"Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, . CREDO Investigatorset al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA2002;288:2411-2420.","DOI":"10.1001\/jama.288.19.2411"},{"key":"2020022800545610900_R3","doi-asserted-by":"crossref","unstructured":"Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med2002;252:233-238.","DOI":"10.1046\/j.1365-2796.2002.01027.x"},{"key":"2020022800545610900_R4","doi-asserted-by":"crossref","unstructured":"Gurbel P, Bliden K, Hiatt B, O\u2019Connor C. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation2003;107:2908-2913.","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"2020022800545610900_R5","doi-asserted-by":"crossref","unstructured":"Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost2003;89:783-787.","DOI":"10.1055\/s-0037-1613462"},{"key":"2020022800545610900_R6","doi-asserted-by":"crossref","unstructured":"Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation2004;109:3171-3175.","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"2020022800545610900_R7","doi-asserted-by":"crossref","unstructured":"Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation2004;109:166-171.","DOI":"10.1161\/01.CIR.0000112378.09325.F9"},{"key":"2020022800545610900_R8","doi-asserted-by":"crossref","unstructured":"Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation2003;108:989-995.","DOI":"10.1161\/01.CIR.0000085073.69189.88"},{"key":"2020022800545610900_R9","doi-asserted-by":"crossref","unstructured":"Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation2003;107:32-37.","DOI":"10.1161\/01.CIR.0000047060.60595.CC"},{"key":"2020022800545610900_R10","doi-asserted-by":"crossref","unstructured":"Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol2004;24:1980-1987.","DOI":"10.1161\/01.ATV.0000145980.39477.a9"},{"key":"2020022800545610900_R11","doi-asserted-by":"crossref","unstructured":"Wenaweser P, Hess O, Meier B. Thienopyridines, a safety net with holes in it. Catheter Cardiovasc Interv2003;59:303-304.","DOI":"10.1002\/ccd.10585"},{"key":"2020022800545610900_R12","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation2004;109:3064-3067.","DOI":"10.1161\/01.CIR.0000134701.40946.30"},{"key":"2020022800545610900_R13","doi-asserted-by":"crossref","unstructured":"Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets\u2014definition and detection of ticlopidine\/clopidogrel effects. Thromb Haemost1999;82:1145-1152.","DOI":"10.1055\/s-0037-1614344"},{"key":"2020022800545610900_R14","doi-asserted-by":"crossref","unstructured":"Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv2003;59:295-302.","DOI":"10.1002\/ccd.10497"},{"key":"2020022800545610900_R15","doi-asserted-by":"crossref","unstructured":"Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost2004;92:1201-1206.","DOI":"10.1160\/TH04-01-0049"},{"key":"2020022800545610900_R16","doi-asserted-by":"crossref","unstructured":"Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost2005;3:85-92.","DOI":"10.1111\/j.1538-7836.2004.01063.x"},{"key":"2020022800545610900_R17","doi-asserted-by":"crossref","unstructured":"Obergfell A, Strotmann J, Bonz A, Bauersachs J, Ertl G, Walter U, et al. Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis. Thromb Haemost2004;92:1446-1447.","DOI":"10.1055\/s-0037-1614302"},{"key":"2020022800545610900_R18","doi-asserted-by":"crossref","unstructured":"Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol1999;19:2007-2011.","DOI":"10.1161\/01.ATV.19.8.2007"},{"key":"2020022800545610900_R19","doi-asserted-by":"crossref","unstructured":"Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol1998;351:235-246.","DOI":"10.1016\/S0014-2999(98)00305-7"},{"key":"2020022800545610900_R20","doi-asserted-by":"crossref","unstructured":"Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem1998;273:20029-20035.","DOI":"10.1074\/jbc.273.32.20029"},{"key":"2020022800545610900_R21","doi-asserted-by":"crossref","unstructured":"Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation2001;101:2823-2828.","DOI":"10.1161\/01.CIR.101.24.2823"},{"key":"2020022800545610900_R22","doi-asserted-by":"crossref","unstructured":"Rupprecht HJ, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation1998;97:1046-1052.","DOI":"10.1161\/01.CIR.97.11.1046"},{"key":"2020022800545610900_R23","doi-asserted-by":"crossref","unstructured":"Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists\u2014in vitro experience. Clin Chem Lab Med2004;42:25-29.","DOI":"10.1515\/CCLM.2004.006"},{"key":"2020022800545610900_R24","doi-asserted-by":"crossref","unstructured":"Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?. Thromb Res2002;108:43-47.","DOI":"10.1016\/S0049-3848(02)00391-2"},{"key":"2020022800545610900_R25","doi-asserted-by":"crossref","unstructured":"Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost2004;2:2278-2279.","DOI":"10.1111\/j.1538-7836.2004.01046.x"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/6\/957\/32683091\/clinchem0957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/6\/957\/32683091\/clinchem0957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T05:57:45Z","timestamp":1582869465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/6\/957\/5629884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,6,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2004.047050","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,6,1]]},"published":{"date-parts":[[2005,6,1]]}}}